CJC-1295 with DAC 5mg

CJC-1295 with DAC is a synthetic peptide derived from the active portion of growth hormone–releasing hormone (GHRH). It is designed as a long-acting agonist of the GHRH receptor, a signaling pathway that regulates growth hormone release and downstream endocrine activity within the GH/IGF-1 axis [4]. In research environments, the compound is commonly used to study how sustained activation of the GHRH receptor influences hormone signaling, metabolism, and physiological regulation.

The peptide is based on a modified GRF(1-29) sequence but includes an additional structural component known as a Drug Affinity Complex (DAC). This modification allows the peptide to bind circulating albumin after entering biological systems, which slows degradation and reduces rapid clearance from the bloodstream [1]. Because of this albumin-binding mechanism, CJC-1295 with DAC remains active much longer than native GHRH fragments or shorter-acting analogs, making it useful in experimental models that examine extended receptor signaling and endocrine pathway stimulation.

In studies examining the growth hormone axis, activation of the GHRH receptor stimulates intracellular signaling pathways involving cyclic AMP and calcium-dependent secretion in pituitary cells [5]. These signaling events ultimately lead to the release of growth hormone, which then promotes the production of insulin-like growth factor-1 (IGF-1) in the liver and other tissues. Research has shown that CJC-1295 can produce sustained increases in growth hormone signaling while still preserving the natural pulsatile pattern of hormone secretion observed in physiological systems [6].

CJC-1295 with DAC vs CJC-1295 No DAC

CJC-1295 with DAC differs from CJC-1295 No DAC through the presence of the Drug Affinity Complex attached to the peptide's C-terminus. This DAC modification contains a maleimide-linked extension that enables the peptide to associate with circulating albumin, significantly prolonging its persistence in experimental models [1].

Without this albumin-binding modification, the No DAC version behaves more like a short-acting GHRH fragment, producing a shorter signaling window that is useful for studies examining pulsatile receptor activation and rapid signaling responses. By contrast, the DAC variant provides longer receptor exposure, which makes it more appropriate for experimental designs focused on sustained pathway activation, pharmacokinetic modeling, or extended endocrine signaling.

Because both peptides activate the same receptor pathway, researchers often compare them in parallel studies. These comparisons help scientists understand how peptide structure and albumin binding influence signaling duration, receptor activation patterns, and downstream biological responses within the growth hormone regulatory system.

CJC-1295 with DAC: Purity and Stability

CJC-1295 with DAC supplied by NewBioRx is manufactured using controlled solid-phase peptide synthesis (SPPS) processes designed to ensure accurate sequence assembly and batch reproducibility. Following synthesis, the peptide undergoes purification using high-performance liquid chromatography (HPLC) to remove incomplete sequences, synthesis byproducts, and other impurities that can arise during peptide production.

Each batch is analytically verified using techniques such as mass spectrometry and chromatographic profiling to confirm molecular identity and purity levels that typically exceed ≥99.9%. Certificates of Analysis are provided for every production lot, documenting identity verification, purity measurements, and other analytical characteristics relevant to laboratory research workflows.

These quality control procedures help ensure consistent material performance in receptor signaling studies, endocrine pathway research, and biochemical assay systems.

This material is supplied strictly for laboratory research use only and is not intended for human or veterinary use.

CJC-1295 with DAC is a synthetic peptide analog built from a modified GRF(1-29) sequence extended with an additional lysine residue that carries a maleimide-containing drug affinity complex. Functionally, the peptide remains a GHRH receptor agonist, but structurally it differs from CJC-1295 No DAC through this albumin-reactive extension.

The modified backbone and DAC-linked lysine together create a long-acting ligand architecture used in laboratory systems to study prolonged receptor signaling, peptide persistence, and exposure-dependent endocrine responses.

CJC-1295 with DAC: Sequence Designation

CJC-1295 with DAC is commonly described in the literature as a tetrasubstituted hGRF(1-29) analog with an added C terminal lysine bearing a maleimidopropionamide-type DAC modification. In practical research terms, that designation reflects two engineered features: amino acid substitutions within the GRF core to improve stability and receptor-active behavior, and a terminal albumin-binding extension that markedly prolongs peptide residence in experimental systems.

CJC-1295 Chemical Structure

CJC-1295 2D Structure

CJC-1295 3D Structure

Chemical Properties and Registry Information for CJC-1295 with DAC

CJC-1295 with DAC is characterized by the following molecular identifiers and registry data for compound verification and laboratory reference. CJC-1295 with DAC is indexed separately from CJC-1295 without DAC, and regulatory documents note that confusion between the DAC and non-DAC forms is common in submitted documentation, making precise identification especially important.

Property	Value
Name & Synonyms	CJC-1295 with DAC; CJC-1295 DAC; DAC:GRF; long-acting GHRH analog
PubChem CID	91971820
CAS Number	446262-90-4
Molecular Formula	C165H269N47O46
Molecular Weight	3647.2 g/mol
Peptide Length	30 amino acids including DAC-linked terminal lysine
Compound Class	Synthetic peptide analog with drug affinity complex
Primary Targets	Growth hormone releasing hormone receptor (GHRHR)
InChIKey	ZUQGTWKGESAQCD-ZGFIGYLBSA-N
IUPAC Name	Show IUPAC Name ▼ (3S)-4-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S,3R)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-6-[3-(2,5-dioxopyrrol-1-yl)propanoylamino]-1-oxohexan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-[[(2R)-2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]propanoyl]amino]-4-oxobutanoic acid

CJC-1295 with DAC provides a useful experimental model for studying sustained growth hormone releasing hormone receptor signaling and the effect of albumin bioconjugation on peptide pharmacology. The GHRH receptor is a class B G protein coupled receptor that signals primarily through Gs and cyclic AMP pathways, making it a practical system for investigating how ligand engineering alters both receptor activation and exposure duration.

Because CJC-1295 with DAC combines a receptor-active GRF analog core with a serum albumin-binding modification, it enables controlled investigation of prolonged signaling, extended peptide stability, and downstream endocrine pathway responses in laboratory and preclinical model systems.

CJC-1295 with DAC occupies a distinct place in GHRH pathway research because it allows investigators to study sustained receptor engagement rather than the brief signaling pulse associated with native GHRH fragments or shorter-acting analogs. This is important in experimental systems designed to examine how prolonged ligand exposure shapes endocrine signaling, metabolic regulation, tissue remodeling pathways, and time-dependent feedback behavior over extended intervals.

At the center of its research value is the DAC, or Drug Affinity Complex, modification. This maleimide-containing moiety enables covalent binding to circulating serum albumin in research models, creating a long-acting peptide construct that remains available to the GHRH receptor pathway for far longer than standard GRF-based ligands.

As a result, CJC-1295 with DAC is often used when the research question is not simply whether the receptor can be activated, but how persistent low-level stimulation changes signaling behavior across hours or days.

Muscle Development and Body Composition Research

CJC-1295 with DAC is frequently studied in experimental systems that examine how sustained activation of the growth hormone–releasing hormone receptor influences body composition and anabolic signaling. By stimulating the GHRH pathway over extended periods, the peptide promotes downstream activation of the GH/IGF-1 axis, which plays a central role in regulating muscle maintenance, protein synthesis, and tissue growth.

Preclinical work using GHRH knockout mouse models demonstrated that administration of CJC-1295 restored normal growth patterns and normalized body composition parameters, including lean mass and skeletal development [4]. These findings illustrate how sustained GHRH receptor stimulation can support anabolic endocrine signaling in systems where endogenous hormone activity is limited.

Human studies have also shown that CJC-1295 produces prolonged increases in circulating IGF-1 levels after a single dose, with elevations lasting more than a week in healthy subjects [2]. Because IGF-1 is a major mediator of growth hormone's anabolic effects, these prolonged increases make CJC-1295 with DAC useful in research examining muscle metabolism, protein turnover, and the endocrine mechanisms involved in maintaining lean tissue.

Fat Metabolism and Lipid Regulation Studies

Another important area of investigation involves how growth hormone signaling influences lipid metabolism. Growth hormone stimulates lipolysis in adipose tissue, promoting the breakdown of stored triglycerides into free fatty acids that can be used as metabolic fuel.

Studies examining the endocrine effects of CJC-1295 have documented systemic metabolic changes associated with activation of the GH/IGF-1 pathway. Proteomic analysis of serum samples from individuals receiving the peptide revealed alterations in proteins related to lipid transport and metabolism, including apolipoprotein A-I, a major component of high-density lipoproteins [2]. These molecular changes indicate that sustained GH signaling can influence pathways involved in fat mobilization and metabolic regulation.

In laboratory research settings, these effects are investigated to better understand how endocrine signaling influences substrate utilization, fat distribution, and metabolic flexibility. By maintaining elevated GH activity over longer periods, CJC-1295 with DAC provides a useful model for studying the relationship between hormone signaling and fat metabolism.

Growth Hormone Secretion Dynamics and Pulsatility

One unique feature of CJC-1295 is that it can sustain growth hormone signaling while preserving the body's natural pulsatile pattern of hormone release. Studies examining GH secretion patterns after administration of the peptide found that pulsatile GH release continued even during prolonged stimulation of the GHRH receptor [6].

In these studies, baseline growth hormone levels increased substantially while the frequency and amplitude of GH secretory pulses remained largely unchanged. This produced an overall increase in average GH secretion and corresponding elevations in circulating IGF-1 concentrations.

The preservation of physiological pulsatility distinguishes GHRH analog stimulation from direct growth hormone administration, which can suppress the body's natural regulatory rhythms. Because endocrine timing plays a major role in hormone signaling, CJC-1295 with DAC is often used in research examining how prolonged receptor stimulation interacts with natural hormone pulse dynamics.

Bone Formation and Skeletal Signaling Research

The GH/IGF-1 axis is also a critical regulator of skeletal development and bone remodeling. Growth hormone stimulates osteoblast activity and bone matrix formation, while IGF-1 promotes chondrocyte proliferation and mineral deposition in bone tissue.

In animal models lacking endogenous GHRH signaling, administration of CJC-1295 restored normal skeletal growth and bone development [4]. These findings demonstrate how stimulation of the GHRH receptor can reactivate the endocrine pathways responsible for maintaining skeletal structure.

Because of these mechanisms, CJC-1295 with DAC is used in research investigating bone formation, skeletal remodeling, and the role of endocrine signaling in maintaining bone density and structural integrity.

Tissue Repair and Regenerative Signaling

Growth hormone and IGF-1 also influence a wide range of cellular processes involved in tissue repair and regeneration. IGF-1 stimulates cell proliferation, differentiation, and collagen synthesis, which are essential steps in tissue remodeling and wound healing.

Research examining the endocrine effects of CJC-1295 has shown that activation of the GH/IGF-1 pathway alters serum protein profiles associated with growth factor signaling and tissue repair processes [2]. These molecular changes reflect the peptide's systemic influence on protein metabolism and cellular regeneration pathways.

In experimental systems, investigators use CJC-1295 with DAC to explore how sustained endocrine signaling influences connective tissue repair, muscle regeneration, and extracellular matrix remodeling.

Metabolic Regulation and Endocrine Signaling Studies

CJC-1295 with DAC is also used in metabolic research examining how the GH/IGF-1 axis influences glucose metabolism, energy balance, and nutrient partitioning. Growth hormone signaling affects multiple metabolic pathways, including lipid oxidation, protein turnover, and carbohydrate utilization.

Because the peptide maintains elevated GH signaling over extended periods, it provides a useful experimental model for studying how long-acting receptor agonists influence metabolic coordination across multiple tissues. Researchers often examine biomarkers related to glucose handling, lipid metabolism, and protein synthesis to understand how endocrine signaling regulates energy utilization.

At the cellular level, activation of the GHRH receptor stimulates cyclic AMP signaling and downstream pathways that regulate hormone secretion and metabolic gene expression [5]. By maintaining this signaling cascade over longer durations, CJC-1295 with DAC allows investigators to study how sustained endocrine input shapes metabolic pathway behavior in experimental systems.

The functional utility of CJC-1295 with DAC is defined by its ability to shift the research focus from acute signaling spikes to integral exposure (Area Under the Curve). By leveraging a combination of sequence stabilization and bioconjugation, the compound maintains a steady-state presence that is difficult to replicate with unmodified peptides.

Molecular Stability and DPP-IV Resistance

While the DAC (Drug Affinity Complex) handles systemic persistence, the peptide core itself is often engineered for enhanced durability. In many research preparations, the substitution of D-Alanine at the second position of the GRF(1-29) sequence significantly increases resistance to dipeptidyl peptidase IV (DPP-IV), the primary enzyme responsible for the rapid cleavage of endogenous GHRH.

This has important research implications, as it creates a dual-layer defense that prevents enzymatic degradation at the molecular level and another (the DAC) that prevents renal clearance at the systemic level.

Target Engagement: The "ECD Trap" and Transmembrane Activation

CJC-1295 with DAC interacts with the growth hormone releasing hormone receptor, a class B G protein coupled receptor expressed primarily on pituitary somatotroph cells. The receptor normally recognizes endogenous GHRH, and structural work has shown that peptide binding is mediated through coordinated interactions between the ligand, the receptor extracellular domain, and the transmembrane bundle.

CJC-1295 with DAC preserves the receptor-binding features of the modified GRF sequence, allowing it to activate the same target while altering the ligand's residence time in the biological system through albumin association rather than through a different receptor mechanism [6].

In other words, the C-terminal region of the peptide first docks with the extracellular domain (ECD) of the receptor. This "traps" the ligand, positioning the N-terminus to penetrate the receptor's transmembrane bundle. Because the DAC moiety is covalently linked to serum albumin, the peptide is not "free-floating." Instead, it exists in a state of dynamic equilibrium. As the receptor engages a peptide molecule, the albumin carrier acts as a circulating reservoir, constantly replenishing the local ligand concentration at the pituitary somatotrophs without the need for exogenous re-administration.

Downstream Signaling Pathways

After target engagement, GHRHR couples predominantly to Gs and stimulates adenylyl cyclase, increasing intracellular cyclic AMP. This activates protein kinase A and related downstream effectors involved in ion channel regulation, transcriptional responses, and endocrine secretory signaling. In pituitary systems, cyclic AMP signaling is linked to membrane excitability and calcium influx, so CJC-1295 with DAC is often evaluated through cAMP assays, calcium imaging, reporter-gene systems, and hormone secretion readouts.

The distinguishing feature of the DAC analog is that these signaling events can be observed over a longer effective exposure window than with non-DAC ligands.

Cellular Effects in Experimental Models

In biochemical assays, cell culture systems, and animal studies, CJC-1295 with DAC has been associated with sustained activation of endocrine signaling pathways downstream of GHRHR. Experimental models have measured prolonged peptide persistence, extended pathway stimulation, and durable receptor-dependent endocrine responses compared with shorter-acting GHRH analogs.

Because the DAC group influences peptide disposition without changing the primary receptor target, CJC-1295 with DAC is especially useful for isolating the effects of extended ligand exposure on receptor pharmacology and downstream signaling behavior.

CJC-1295 with DAC is often evaluated alongside other GHRH pathway ligands and engineered endocrine signaling peptides. In laboratory research, these comparisons help clarify how peptide structure, receptor affinity, and exposure duration influence signaling outcomes across the same receptor system.

CJC-1295 with DAC is differentiated mainly by its albumin-binding DAC architecture. That feature makes it especially useful when investigators need a ligand that remains bioactive over longer intervals, allowing steady-state or extended-duration receptor signaling experiments that are harder to model with shorter-acting peptides.

By contrast, CJC-1295 No DAC is usually the better option for brief exposure studies, while Sermorelin remains useful as a closer analog of the endogenous hormone sequence. Related peptide tools may also be available within the NewBioRx catalog to support endocrine signaling and receptor pharmacology research.

CJC-1295 with DAC should be handled in accordance with standard research peptide protocols. As a compound whose effects in humans are not fully characterized, appropriate laboratory precautions and chemical hygiene practices should be observed at all times.

This compound should be handled by qualified researchers using appropriate chemical hygiene and peptide handling procedures. This compound is supplied as a lyophilized peptide and should be stored under controlled conditions to help preserve peptide structure, analytical purity, and chemical stability over time.

For long-term storage, the material should be kept at −4 °F (−20 °C) or below and protected from heat, moisture, and direct light. According to existing studies, xpected stability under storage below −20 °C, which aligns with standard peptide handling practice for this class of research compounds.

After reconstitution, peptide solutions should be stored at 36–46 °F (2–8 °C). Proper refrigerated storage and careful handling help reduce degradation pathways such as hydrolysis, oxidation, and peptide aggregation during short-term laboratory use.

Handling Guidelines

Proper handling practices help maintain peptide integrity throughout storage and preparation.

• Store lyophilized material at −4 °F (−20 °C) or below
• Allow vial to reach room temperature before opening
• Protect from light, heat, and humidity
• Use sterile laboratory equipment during preparation
• Avoid repeated freeze-thaw cycles
• Label reconstituted samples with preparation date and concentration

These practices help support sample consistency and experimental reproducibility.

Reconstitution Guidelines

Standard peptide preparation procedures should be followed to help maintain solution quality and molecular stability.

• Reconstitute with sterile bacteriostatic water or appropriate laboratory buffer
• Add solvent slowly along the vial wall to minimize foaming
• Avoid vigorous agitation or vortexing
• Gently swirl until the peptide is dissolved
• Store reconstituted solutions at 36–46 °F (2–8 °C)
• Prepare aliquots where appropriate to reduce freeze-thaw cycles

Careful reconstitution helps maintain peptide stability and supports more reliable handling in laboratory workflows.

Laboratory Safety Protocols

General chemical safety practices should be followed when handling research peptides in laboratory environments.

• Wear PPE including gloves, lab coat, and protective eyewear
• Handle compounds within approved laboratory workspaces
• Avoid inhalation, ingestion, or direct contact
• Dispose of materials according to institutional chemical waste procedures
• Maintain proper labeling and documentation for stored research compounds

These practices support safe laboratory operation and appropriate research material control.

All products supplied by NewBioRx are intended strictly for laboratory research and development use only and are not approved for human or veterinary use.

What is the difference between CJC-1295 with DAC and CJC-1295 No DAC?

CJC-1295 with DAC and CJC-1295 No DAC share the same core GHRH pathway target but differ in molecular architecture and experimental persistence. The DAC version includes an albumin-binding drug affinity complex that markedly prolongs peptide residence in biological systems, while the non-DAC version behaves as a shorter-acting modified GRF analog. This makes the DAC form more suitable for sustained signaling studies and the non-DAC form more useful for pulse-like receptor activation experiments.

What does the DAC modification do?

The DAC modification adds a maleimide-bearing lysine extension that enables in vivo bioconjugation to serum albumin. In practical research terms, this reduces rapid peptide clearance and extends the effective exposure window of the agonist. The result is a long-acting GHRH analog that can be used to study prolonged receptor stimulation, persistence-dependent endocrine signaling, and peptide stabilization strategies in experimental systems.

What makes CJC-1295 with DAC different from other GHRH analog peptides?

The defining feature of CJC-1295 with DAC is the Drug Affinity Complex modification that allows the peptide to bind circulating albumin. This albumin association slows peptide clearance and allows the compound to remain active for longer periods compared with shorter-acting GHRH fragments. Because of this extended activity, it is often used in research models that require sustained receptor stimulation rather than short signaling pulses.

What purity testing is performed on CJC-1295 with DAC?

CJC-1295 with DAC supplied by NewBioRx is produced through controlled peptide synthesis and analytical verification processes appropriate for research materials. Batch documentation usually includes chromatographic purity analysis, identity confirmation, and related quality-control data that support long-term research with consistently pure, high-quality compounds. Certificates of Analysis are available on the product pages for review so that researchers can confirm that the specifications align with the expected chemical identity and quality profile.

How should CJC-1295 with DAC be stored before and after reconstitution?

Lyophilized CJC-1295 with DAC should typically be stored at −4 °F (−20 °C) or below in a sealed vial protected from heat, moisture, and light. After reconstitution, peptide solutions are generally stored at 36–46 °F (2–8 °C) and handled carefully to reduce degradation related to hydrolysis, oxidation, or aggregation. Aliquoting may be appropriate when repeated use is expected.

Why do researchers choose CJC-1295 with DAC for sustained signaling studies?

Researchers often choose CJC-1295 with DAC when experimental design depends on extended receptor exposure rather than a short signaling pulse. Because the peptide is engineered to associate with albumin, it can remain available in the system for longer intervals than non-DAC analogs. That makes it useful for studying prolonged endocrine pathway stimulation, persistence-sensitive receptor pharmacology, and time-course effects in biochemical and preclinical models.

Is CJC-1295 with DAC available alongside related GHRH analogs at NewBioRx?

Yes. The NewBioRx peptide catalog also lists related endocrine research compounds including CJC-1295 No DAC 10mg and Sermorelin 10mg, which can be useful for comparative GHRH receptor signaling studies. That allows laboratories to evaluate shorter-acting and longer-acting ligand architectures within the same general signaling pathway.

What is CJC-1295 with DAC used for in research?

CJC-1295 with DAC is commonly used in laboratory studies that investigate growth hormone signaling and the regulation of the GH/IGF-1 axis. Because the DAC modification extends the peptide's activity, researchers often use it to examine sustained GHRH receptor activation, endocrine feedback behavior, and long-duration signaling patterns in metabolic or endocrine research models.

All products supplied by NewBioRx are intended strictly for research and development use. These materials are provided for laboratory investigation and scientific experimentation and are not supplied for use in humans or animals.

This product is not a drug, food, dietary supplement, medical device, or cosmetic. It has not been approved by the U.S. Food and Drug Administration (FDA) for medical, diagnostic, or therapeutic use. Any statements regarding the compound are derived from published scientific literature and have not been evaluated by the FDA. These materials are not intended to diagnose, treat, cure, or prevent any disease.

Materials supplied by NewBioRx must be handled only by qualified professionals trained in laboratory research procedures. The introduction of this product into humans or animals is strictly prohibited and may violate applicable laws and regulations.

Researchers and institutions are responsible for ensuring that the purchase, handling, storage, use, and disposal of research materials comply with all applicable federal, state, and local regulations, as well as institutional policies governing laboratory research.

1. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Jetté L, Léger R, Thibaudeau K, Benquet C, Robitaille M, Pellerin I, Paradis V, van Wyk P, Pham K, Bridon DP. Endocrinology, 2005 Jul;146(7):3052–3058. https://doi.org/10.1210/en.2004-1286

2. Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Sackmann-Sala L, Ding J, Frohman LA, Kopchick JJ. Growth Hormone & IGF Research, 2009 Dec;19(6):471–477. https://doi.org/10.1016/j.ghir.2009.03.001

3. Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Sackmann-Sala L, Ding J, Frohman LA, Kopchick JJ. Growth Hormone & IGF Research, 2009 Dec;19(6):471–477. https://doi.org/10.1016/j.ghir.2009.03.001

4. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. Alba M, Fintini D, Sagazio A, Lawrence B, Castaigne JP, Frohman LA, Salvatori R. American Journal of Physiology - Endocrinology and Metabolism, 2006 Dec;291(6):E1290–E1294. https://doi.org/10.1152/ajpendo.00201.2006

5. Structural basis for activation of the growth hormone-releasing hormone receptor. Zhou F, Zhang H, Cong Z, et al. Nature Communications, 2020;11:5205. https://doi.org/10.1038/s41467-020-18945-0

6. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. Ionescu M, Frohman LA. Journal of Clinical Endocrinology & Metabolism, 2006 Dec;91(12):4792–4797. https://doi.org/10.1210/jc.2006-1702